Verona Pharma 2021 COPD Respiratory Therapy Investor Presentation

Verona Pharma presents ensifentrine, a Phase 3 first-in-class inhaled PDE3/PDE4 inhibitor candidate for COPD maintenance treatment. The company targets a ~$10.5B US market with over 1 million symptomatic patients despite existing dual/triple therapies, highlighting significant unmet medical need and commercial opportunity.